FibroGen Inc [NASDAQ: FGEN] price surged by 9.29 percent to reach at $0.04. The company report on November 6, 2023 at 4:01 PM that FibroGen Reports Third Quarter 2023 Financial Results.
Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer.
Third quarter net revenue of $40.1 million, an increase of 155% year over year.
A sum of 5224382 shares traded at recent session while its average daily volume was at 4.10M shares. FibroGen Inc shares reached a high of $0.4295 and dropped to a low of $0.3454 until finishing in the latest session at $0.42.
The one-year FGEN stock forecast points to a potential upside of 23.64. The average equity rating for FGEN stock is currently 3.60, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on FibroGen Inc [FGEN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FGEN shares is $0.55 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FGEN stock is a recommendation set at 3.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for FibroGen Inc shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on August 08, 2023.
The Average True Range (ATR) for FibroGen Inc is set at 0.09, with the Price to Sales ratio for FGEN stock in the period of the last 12 months amounting to 0.26.
FGEN Stock Performance Analysis:
FibroGen Inc [FGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.72. With this latest performance, FGEN shares dropped by -30.18% in over the last four-week period, additionally sinking by -97.65% over the last 6 months – not to mention a drop of -97.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FGEN stock in for the last two-week period is set at 34.38, with the RSI for the last a single of trading hit 34.44, and the three-weeks RSI is set at 32.10 for FibroGen Inc [FGEN]. The present Moving Average for the last 50 days of trading for this stock 0.7139, while it was recorded at 0.4428 for the last single week of trading, and 10.5036 for the last 200 days.
Insight into FibroGen Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and FibroGen Inc [FGEN] shares currently have an operating margin of -213.90 and a Gross Margin at +85.59. FibroGen Inc’s Net Margin is presently recorded at -208.66.
Return on Total Capital for FGEN is now -133.21, given the latest momentum, and Return on Invested Capital for the company is -150.31. Return on Equity for this stock declined to -312.90, with Return on Assets sitting at -42.44. Additionally, FGEN Total Debt to Total Capital is recorded at 125.08, with Total Debt to Total Assets ending up at 17.53.
Reflecting on the efficiency of the workforce at the company, FibroGen Inc [FGEN] managed to generate an average of -$496,037 per employee. Receivables Turnover for the company is 6.75 with a Total Asset Turnover recorded at a value of 0.20.FibroGen Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.54 and a Current Ratio set at 1.74.
FibroGen Inc [FGEN] Institutonal Ownership Details
The top three institutional holders of FGEN stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in FGEN stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in FGEN stock with ownership which is approximately 5.7994%.
